retatrutide clinical trial data Reta & dosing — a must read (Reta) isn't just another GLP-1. It's a triple-agonist peptide studied in Phase 3 trials for metabolic health — targeting GLP-1, GIP ESC 2024: Retatrutide improves lipid

Retatrutide is the agonist of GLP-1 receptor, GIP receptor, and glucagon (GCG) receptor, which can reduce body weight and improve blood glucose by subcutaneous injection once a week(Rosenstock et al 2023)

As of 2025, retatrutide is still in Phase 3 clinical trials

( A ) ATP generation and ( B ) intracellular cAMP accumulation were analyzed as detailed in the Supplemental Methods from WT sAC +/+ caSMCs incubated for 10 minutes with 0.1 nM to 1 M GLP-1(2836) or scrambled control

Why it matters: A number without monitoring rules can be misleading

Our medical aesthetics in Las Vegas are led by Teresa Hernandez, MSN FNP-BC, who also trains other injectors in advanced technique